Updated: Apr 16, 2020
Our company's central mission is to promote proper, timely diagnostics across the medical fields. It's why we spend our days at Luna focused on every step of the diagnostic workflow: from sample collection, through sample preparation, and all the way to test's readout. COVID-19 has demonstrated the value of nucleic acid-based testing. Just 3 weeks after the sequence of SARS-CoV-2 was shared, the CDC already had the first in vitro diagnostic deployed under an Emergency Use Authorization in the United States. As cases have climbed, the demand for testing too has risen at an unprecedented pace. When the shortages of testing reagents became apparent, labs around the globe looked for an alternative. We're happy to do our part. We quickly switched gears and developed kits capable of extracting viral RNA from SARS-CoV-2. (Check back later this week for the official product launch!). And using our deep knowledge in the area, we're able to tune our offerings to meet many of our client's exact specifications and minimize any disruption to their workflow. We're on track to have shipped out over 300,000 extractions worth of reagents and labware by the end of this week. We've helped get tests out in the US, Canada and Europe. We're extremely proud of this number and are working hard to bring it even higher. If you're struggling to find extraction reagents for your diagnostic workflow, or you need an extraction solution that's a better fit for you, please contact us!
Stay safe, -Ben